This website is intended for healthcare professionals only.
PERSONALIZED TREATMENT TO MAXIMISE OUTCOMES FOR PATIENTS WITH CCA
Professor Gerald Prager, Associate Professor of Oncology, Head of Gastrointestinal Cancer Program, Medical University of Vienna, Austria Prof Cindy Neuzillet Head of GI Oncology – Curie Institute, France
This webinar focuses on precision medicine in CCA treatment - to optimize patient outcomes and improve survival rates. An interactive clinical patient case is presented throughout the webinar to illustrate the importance of molecular testing and precision medicine.
Indication: CCA
Key points covered
This webinar highlights the need for precision medicine based on molecular characterization. It covers the following points:
Targeted treatment shows promise for patients with CCA, with already several approved therapies.
More specifically, ivosidenib has shown to significantly improve survival and maintain QoL in CCA patients with IDH1 mutations.
An interactive clinical case is also presented, with a focus on the importance of early molecular testing.
Webinar Replay
Featured Speakers
Prof Gerald Prager
Associate professor of oncology – Head of the Gastrointestinal Cancer Program – Medical University of Vienna, Austria
research and (tumor-) angiogenesis and his work has been honored by more than 20 international awards and published in highly renowned international journals. Prof Prager is also a member of the ESMO Scientific Committee.
Prof Cindy Neuzillet
Head of GI oncology – Curie Institute, France
